Loading stock data…
Vanda Pharmaceuticals Inc. (VNDA)
$5.33-0.10 (-1.84%)
Market ClosedLast close Sep 8
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vanda Pharmaceuticals Inc. in the Healthcare sector is trading at $5.33 with a market capitalization of $325M. Wall Street consensus targets $12.19 (4 analysts), implying a +128.7% move over the next 12 months. The stock is currently near its 52-week low of $4.27, remaining 19.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +128.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.72M↓ | $57.22M↑ | $56.26M↑ | $52.59M↑ | $50.04M |
| Gross Profit | $48.56M↓ | $53.38M↑ | $53.30M↑ | $49.85M↑ | $46.52M |
| Operating Income | -$50.22M↓ | -$40.35M↓ | -$31.28M↑ | -$38.50M↑ | -$41.03M |
| Net Income | -$48.57M↑ | -$141.19M↓ | -$22.59M↑ | -$27.21M↑ | -$29.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$324.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-124.83%
Volume
Today's trading volume
620,187
Recent News
Vanda (VNDA) Q2 2026 Earnings Call Transcript
Fanapt surges 23% as Vanda expands psychiatry franchise amid pipeline progress.
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals (NASDAQ:VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it exp
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary
Moby summary of Vanda Pharmaceuticals Inc.'s Q2 2026 earnings call
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?